Zevra Therapeutics (ZVRA) Gross Margin (2019 - 2026)
Zevra Therapeutics (ZVRA) reported Gross Margin of 94.76% for Q1 2026, up 135.0% on a YoY basis from 40.32% in Q1 2025, and down 0.83% quarter-over-quarter from 95.55% in Q4 2025.
Zevra Therapeutics (ZVRA) Gross Margin (2019 - 2026) Analysis & Trends
Zevra Therapeutics has reported Gross Margin for 7 years, with the latest figure at 94.76% in Q1 2026.
- For the quarter ending Q1 2026, Gross Margin rose 135.0% year-over-year to 94.76%; the trailing twelve-month figure through Mar 2026 stood at 86.07% (up 727.0% YoY), and the FY2025 full-year result was 84.52%, up 1593.0% from the prior year.
- Gross Margin for Q1 2026 stood at 94.76%, down from 95.55% in the prior quarter.
- The five-year high for Gross Margin was 99.8% in Q1 2022, with the low at 18.8% in Q2 2024.
- Historically, Gross Margin has averaged 82.17% across 5 years, with a median of 94.76% in 2026.
- Annual changes were most pronounced in 2024 — Gross Margin sank 7321 bps — and 2025, when it jumped 5758 bps.
- Zevra Therapeutics' Gross Margin stood at 99.0% in 2022, then decreased by 9 bps to 90.5% in 2023, then decreased by 2 bps to 88.63% in 2024, then increased by 8 bps to 95.55% in 2025, then declined by 1 bps to 94.76% in 2026.
- The last three Gross Margin figures came in at 94.76% (Q1 2026), 95.55% (Q4 2025), and 95.25% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 79.04% |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 86.85% |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | Zevra Therapeutics | 704.96 Mn | 504.34 Mn | 34.30 Mn | 94.76% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 94.76% |
| Dec 31, 2025 | 95.55% |
| Sep 30, 2025 | 95.25% |
| Jun 30, 2025 | 52.17% |
| Mar 31, 2025 | 93.41% |
| Dec 31, 2024 | 88.63% |
| Sep 30, 2024 | 37.67% |
| Jun 30, 2024 | 18.80% |
| Mar 31, 2024 | 94.85% |
| Dec 31, 2023 | 90.50% |
| Sep 30, 2023 | 95.03% |
| Jun 30, 2023 | 92.01% |
| Mar 31, 2023 | 96.06% |
| Dec 31, 2022 | 99.00% |
| Sep 30, 2022 | 95.09% |
| Jun 30, 2022 | 58.33% |
| Mar 31, 2022 | 99.80% |
| Dec 31, 2021 | 97.71% |
| Sep 30, 2021 | 100.00% |
| Jun 30, 2021 | 91.66% |